Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piero Berti

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2009
Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithiumDaniele Barbaro, Mariano Grosso, Giuseppe Boni, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2007
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up studyRossella Elisei, Barbara Cosci, Cristina Romei, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2011
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single centerRossella Elisei, Cristina Romei, Giulia Renzini, et al.
Oncology Reports|January 14, 2004
Regulation of telomerase and its hTERT messenger in colorectal cancerLaura Boldrini, Pinuccia Faviana, Silvia Gisfredi, et al.
Molecular Biosystems|December 25, 2010
A proteomic approach to study parathyroid glandsLaura Giusti, Filomena Cetani, Federica Ciregia, et al.
Biochemical Pharmacology|April 5, 2011
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cellsGuido Bocci, Anna Fioravanti, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2010
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancerAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
International Journal of Cancer|January 25, 2002
Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangementFulvio Basolo, Riccardo Giannini, Antonio Toniolo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2009
Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithiumDaniele Barbaro, Mariano Grosso, Giuseppe Boni, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2007
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up studyRossella Elisei, Barbara Cosci, Cristina Romei, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2011
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single centerRossella Elisei, Cristina Romei, Giulia Renzini, et al.
Oncology Reports|January 14, 2004
Regulation of telomerase and its hTERT messenger in colorectal cancerLaura Boldrini, Pinuccia Faviana, Silvia Gisfredi, et al.
Molecular Biosystems|December 25, 2010
A proteomic approach to study parathyroid glandsLaura Giusti, Filomena Cetani, Federica Ciregia, et al.
Biochemical Pharmacology|April 5, 2011
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cellsGuido Bocci, Anna Fioravanti, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2010
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancerAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
International Journal of Cancer|January 25, 2002
Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangementFulvio Basolo, Riccardo Giannini, Antonio Toniolo, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 6